Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2007-006645-41-NL
EUCTR2007-006645-41-NL
Active, not recruiting
Not Applicable

The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPS

Sint Lucas Andreas Hospital0 sitesMay 29, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondary
DrugsZemplarEtalpha

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Secondary hyperparathyroidism
Sponsor
Sint Lucas Andreas Hospital
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 29, 2008
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Sint Lucas Andreas Hospital

Eligibility Criteria

Inclusion Criteria

  • •\- Hemodialysis patients of 18 years and older.
  • •\- Secondary hyperparathyroidism.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Severe hypercalcemia (Ca2\+ \> 2,65 mmol/L)
  • •Severe hepatic dysfunction
  • •Overdosage of digoxin
  • •Hypersensitivity to vitamin D or overdosage of vitmain D
  • •Parathyroidectomia in the past
  • •\< 18 years of age
  • •Mentall illness

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 4
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149
NL-OMON31628Sint Lucas Andreas Ziekenhuis114
Not yet recruiting
Not Applicable
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism
NL-OMON24070Het Sint Lucas Andreas ziekenhuis114
Not yet recruiting
Not Applicable
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patients
NL-OMON24822Sint Lucas Andreas ziekenhuis114
Active, not recruiting
Not Applicable
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2013-001326-25-ESFundación SENEFRO
Terminated
Phase 4
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysis
NCT00664430Abbott13